Jan A LubiÅ„ski

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8584719/publications.pdf

Version: 2024-02-01

535	42,316	2832	4305
papers	citations	97 h-index	179 g-index

556	556	556	43143
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
2	Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. American Journal of Human Genetics, 2015, 97, 576-592.	2.6	1,098
3	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	9.4	960
4	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	13.7	929
5	Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. Journal of Clinical Oncology, 2010, 28, 2512-2519.	0.8	877
6	Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet, The, 2011, 378, 2081-2087.	6.3	849
7	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
8	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
9	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	3.0	596
10	Partitioning Heritability of Regulatory and Cell-Type-Specific Variants across 11 Common Diseases. American Journal of Human Genetics, 2014, 95, 535-552.	2.6	569
11	Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a <EMPH TYPE="ITAL">BRCA1</EMPH> or <EMPH TYPE="ITAL">BRCA2</EMPH> Mutation. JAMA - Journal of the American Medical Association, 2006, 296, 185.	3.8	544
12	Breast Cancer Risk Genes â€" Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	13.9	532
13	Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. Journal of Clinical Oncology, 2014, 32, 1547-1553.	0.8	523
14	Lung cancer susceptibility locus at 5p15.33. Nature Genetics, 2008, 40, 1404-1406.	9.4	514
15	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	9.4	513
16	Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2010, 28, 375-379.	0.8	500
17	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
18	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	9.4	492

#	Article	IF	Citations
19	Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer. Journal of Clinical Oncology, 2012, 30, 372-379.	0.8	445
20	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell, 2019, 179, 964-983.e31.	13.5	430
21	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	3.0	428
22	Genome-wide association study identifies three loci associated with melanoma risk. Nature Genetics, 2009, 41, 920-925.	9.4	422
23	Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study. Journal of Clinical Oncology, 2005, 23, 7491-7496.	0.8	408
24	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
25	Genome-wide association studies identify four ER negativeâ€“specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	9.4	374
26	Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nature Genetics, 2014, 46, 736-741.	9.4	360
27	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, 47, 1294-1303.	9.4	357
28	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
29	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	9.4	321
30	Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2002, 94, 1773-1779.	3.0	318
31	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
32	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 2008, 122, 2017-2022.	2.3	306
33	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
34	Genetic Structure of Europeans: A View from the Northâ€“East. PLoS ONE, 2009, 4, e5472.	1.1	279
35	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	9.4	276
36	Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome. New England Journal of Medicine, 2008, 359, 2567-2578.	13.9	273

#	Article	IF	Citations
37	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. Journal of Clinical Oncology, 2015, 33, 2901-2907.	0.8	266
38	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics, 2011, 43, 785-791.	9.4	265
39	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
40	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	9.4	264
41	Dose-Response Association of CD8⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	3.4	260
42	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	9.4	256
43	Tamoxifen and contralateral breast cancer inBRCA1 andBRCA2 carriers: An update. International Journal of Cancer, 2006, 118, 2281-2284.	2.3	246
44	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
45	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	9.4	235
46	Genome-wide association study identifies three new melanoma susceptibility loci. Nature Genetics, 2011, 43, 1108-1113.	9.4	230
47	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
48	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
49	Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncology, The, 2007, 8, 26-34.	5.1	220
50	Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nature Genetics, 2011, 43, 60-65.	9.4	220
51	Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet, The, 2020, 395, 1855-1863.	6.3	220
52	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nature Genetics, 2015, 47, 987-995.	9.4	218
53	RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	2.6	217
54	Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer. Journal of Clinical Oncology, 2011, 29, 3747-3752.	0.8	207

#	Article	IF	Citations
55	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	2.6	201
56	Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nature Communications, 2020, 11, 1293.	5.8	196
57	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	0.9	195
58	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell, 2021, 39, 361-379.e16.	7.7	189
59	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	9.4	184
60	Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. Journal of the National Cancer Institute, 2008, 100, 1361-1367.	3.0	179
61	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Research, 2012, 14, R110.	2.2	179
62	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
63	Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 4101-4105.	3.3	173
64	A high proportion of founderBRCA1mutations in Polish breast cancer families. International Journal of Cancer, 2004, 110, 683-686.	2.3	170
65	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.4	169
66	Germline RECQL mutations are associated with breast cancer susceptibility. Nature Genetics, 2015, 47, 643-646.	9.4	168
67	Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group. Journal of Clinical Oncology, 2008, 26, 1093-1097.	0.8	161
68	Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	160
69	A Genome-Wide Association Study of Upper Aerodigestive Tract Cancers Conducted within the INHANCE Consortium. PLoS Genetics, 2011, 7, e1001333.	1.5	158
70	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
71	Effect of pregnancy as a risk factor for breast cancer inBRCA1/BRCA2 mutation carriers. International Journal of Cancer, 2005, 117, 988-991.	2.3	152
72	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	1.4	152

#	Article	IF	Citations
73	Age- and Tumor Subtypeâ€“Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	0.8	152
74	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	0.9	148
75	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	5.8	144
76	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	9.4	138
77	A Novel Founder CHEK2 Mutation is Associated with Increased Prostate Cancer Risk: Table 1. Cancer Research, 2004, 64, 2677-2679.	0.4	137
78	Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncology, The, 2015, 16, 638-644.	5.1	137
79	The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecologic Oncology, 2007, 104, 7-10.	0.6	135
80	Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 601-610.	1.1	130
81	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
82	Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype. Cancer Cell, 2019, 35, 256-266.e5.	7.7	123
83	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncology, 2018, 4, 1059.	3.4	121
84	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
85	Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. American Journal of Human Genetics, 2018, 102, 1185-1194.	2.6	119
86	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	1.4	118
87	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Medicine, 2016, 13, e1002105.	3.9	118
88	Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer. Journal of Clinical Oncology, 2013, 31, 3191-3196.	0.8	112
89	A Range of Cancers Is Associated with the rs6983267 Marker on Chromosome 8. Cancer Research, 2008, 68, 9982-9986.	0.4	111
90	A variant in FTO shows association with melanoma risk not due to BMI. Nature Genetics, 2013, 45, 428-432.	9.4	111

#	Article	IF	Citations
91	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	0.9	111
92	The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length. Journal of the National Cancer Institute, 2014, 106, .	3.0	109
93	On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. European Journal of Human Genetics, 2011, 19, 300-306.	1.4	107
94	The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study. Gynecologic Oncology, 2013, 130, 127-131.	0.6	106
95	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nature Communications, 2017, 8, 15724.	5.8	106
96	The NOD2 3020insC Mutation and the Risk of Colorectal Cancer: Table 1. Cancer Research, 2004, 64, 1604-1606.	0.4	105
97	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	5.8	105
98	Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncology, The, 2006, 7, 402-406.	5.1	104
99	Germline deletions in the EPCAM gene as a cause of Lynch syndrome â€“ literature review. Hereditary Cancer in Clinical Practice, 2013, 11, 9.	0.6	104
100	Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2mutation carriers. Breast Cancer Research, 2005, 7, R833-43.	2.2	103
101	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Research and Treatment, 2015, 150, 71-80.	1.1	103
102	A deletion in CHEK2 of 5,395Âbp predisposes to breast cancer in Poland. Breast Cancer Research and Treatment, 2007, 102, 119-122.	1.1	102
103	PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Research and Treatment, 2011, 127, 861-869.	1.1	102
104	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. British Journal of Cancer, 2019, 121, 15-21.	2.9	101
105	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Human Molecular Genetics, 2013, 22, 2520-2528.	1.4	100
106	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	3.0	99
107	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	2.6	98
108	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	5.8	98

#	Article	IF	Citations
109	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	2.2	97
110	CHEK2mutations and the risk of papillary thyroid cancer. International Journal of Cancer, 2015, 137, 548-552.	2.3	97
111	Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncology, The, 2012, 13, 1242-1249.	5.1	95
112	No evidence that protein truncating variants inBRIP1are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 2016, 53, 298-309.	1.5	94
113	Suspected hereditary nonpolyposis colorectal cancer. Diseases of the Colon and Rectum, 1999, 42, 710-715.	0.7	93
114	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
115	Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R42.	2.2	92
116	Cancer variation associated with the position of the mutation in the BRCA2 gene. Familial Cancer, 2002, 3, 1-10.	0.9	91
117	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	2.6	91
118	MiRNAâ€362â€3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer. International Journal of Cancer, 2013, 133, 67-78.	2.3	91
119	Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. Journal of Clinical Oncology, 2015, 33, 3591-3597.	0.8	91
120	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
121	Novel mutations in theLKB1/STK11 gene in Dutch Peutz-Jeghers families. Human Mutation, 1999, 13, 476-481.	1.1	89
122	Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations. Journal of the National Cancer Institute, 2010, 102, 1874-1878.	3.0	89
123	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
124	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
125	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
126	Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a caseâ€“control study. Cancer Causes and Control, 2008, 19, 1111-1119.	0.8	87

#	Article	IF	Citations
127	Hereditary ovarian cancer in Poland. International Journal of Cancer, 2003, 106, 942-945.	2.3	82
128	Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Research and Treatment, 2006, 95, 105-109.	1.1	82
129	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
130	A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Human Molecular Genetics, 2012, 21, 456-462.	1.4	81
131	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	0.9	81
132	Germline 657del5 mutation in the NBS1 gene in breast cancer patients. International Journal of Cancer, 2003, 106, 379-381.	2.3	80
133	Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clinical Endocrinology, 2008, 69, 621-627.	1.2	80
134	Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype. Journal of Clinical Oncology, 2010, 28, 2505-2511.	0.8	80
135	Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. European Journal of Clinical Pharmacology, 2005, 61, 389-394.	0.8	79
136	Suspected HNPCC and Amsterdam criteria II: evaluation of mutation detection rate, an international collaborative study. International Journal of Colorectal Disease, 2002, 17, 109-114.	1.0	78
137	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78
138	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
139	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	3.0	77
140	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	2.6	76
141	Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. European Journal of Human Genetics, 2011, 19, S6-S44.	1.4	75
142	BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.4	75
143	Coffee consumption and breast cancer risk amongBRCA1 andBRCA2 mutation carriers. International Journal of Cancer, 2006, 118, 103-107.	2.3	73
144	Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes and Control, 2005, 16, 667-674.	0.8	71

#	Article	IF	Citations
145	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ€. Human Molecular Genetics, 2011, 20, 4693-4706.	1.4	71
146	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	0.9	71
147	Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland. Breast Cancer Research and Treatment, 2010, 121, 511-518.	1.1	70
148	BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Research and Treatment, 2010, 119, 201-211.	1.1	70
149	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	1.3	70
150	Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer. Cancer Research and Treatment, 2016, 48, 1056-1064.	1.3	69
151	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
152	Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Research and Treatment, 2014, 143, 579-586.	1.1	68
153	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	1.4	68
154	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2018, 150, 85-91.	0.6	65
155	Genetic characterization of northeastern Italian population isolates in the context of broader European genetic diversity. European Journal of Human Genetics, 2013, 21, 659-665.	1.4	64
156	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	5.8	63
157	Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer, 2011, 117, 1812-1818.	2.0	62
158	Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?. European Journal of Human Genetics, 2007, 15, 237-241.	1.4	61
159	Chemotherapy-Induced Amenorrhea in Patients With Breast Cancer With a BRCA1 or BRCA2 Mutation. Journal of Clinical Oncology, 2013, 31, 3914-3919.	0.8	61
160	The RAD51 135 G>C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA1 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 270-275.	1.1	59
161	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	2.6	59
162	The influence of obesity-related factors in the etiology of renal cell carcinomaâ€"A mendelian randomization study. PLoS Medicine, 2019, 16, e1002724.	3.9	59

#	Article	IF	Citations
163	Increased Rates of Chromosome Breakage in BRCA1 Carriers Are Normalized by Oral Selenium Supplementation. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1302-1306.	1.1	58
164	The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Research and Treatment, 2013, 142, 177-185.	1.1	57
165	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
166	International Lung Cancer Consortium: Coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis, 2010, 31, 625-633.	1.3	56
167	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	3.0	56
168	Factors influencing ovulation and the risk of ovarian cancer in <scp>BRCA1</scp> and <scp>BRCA2</scp> mutation carriers. International Journal of Cancer, 2015, 137, 1136-1146.	2.3	56
169	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a caseâ€“control study. Breast Cancer Research and Treatment, 2016, 155, 365-373.	1.1	55
170	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. International Journal of Cancer, 2011, 128, 2063-2074.	2.3	54
171	Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate, 2015, 75, 1467-1474.	1.2	54
172	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	2.9	54
173	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	1.4	53
174	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	2.9	52
175	Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. Breast Cancer Research and Treatment, 2014, 145, 553-562.	1.1	51
176	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	2.3	51
177	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncology, 2022, 8, e216744.	3.4	51
178	Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer. PLoS ONE, 2014, 9, e96767.	1.1	49
179	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	1.1	49
180	Risk of Ovarian Cancer and the NF-ÎºB Pathway: Genetic Association with IL1A and TNFSF10. Cancer Research, 2014, 74, 852-861.	0.4	48

#	Article	IF	Citations
181	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	5.1	48
182	Smoking and the risk of breast cancer among carriers of BRCA mutations. International Journal of Cancer, 2004, 110, 413-416.	2.3	47
183	The 3020insC allele of NOD2 predisposes to early-onset breast cancer. Breast Cancer Research and Treatment, 2005, 89, 91-93.	1.1	47
184	Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Research and Treatment, 2007, 104, 299-308.	1.1	47
185	Oophorectomy after Menopause and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1089-1096.	1.1	47
186	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
187	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
188	The VEGF_936_C>T 3â€²UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Letters, 2008, 262, 71-76.	3.2	46
189	The risk of gastric cancer in carriers of CHEK2 mutations. Familial Cancer, 2013, 12, 473-478.	0.9	46
190	A Low Selenium Level Is Associated with Lung and Laryngeal Cancers. PLoS ONE, 2013, 8, e59051.	1.1	46
191	Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2007, 105, 221-228.	1.1	45
192	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	0.9	45
193	Mutation analysis of MLH1 and MSH2 genes performed by denaturing high-performance liquid chromatography. Journal of Proteomics, 2002, 51, 89-100.	2.4	44
194	Selenium Supplementation Reduced Oxidative DNA Damage in Adnexectomized BRCA1 Mutations Carriers. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2923-2928.	1.1	44
195	Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in lynch syndrome. Journal of Medical Genetics, 2011, 48, 279-284.	1.5	44
196	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	1.1	44
197	Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecologic Oncology, 2006, 100, 83-88.	0.6	43
198	Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Research, 2016, 18, 22.	2.2	43

#	Article	IF	Citations
199	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
200	A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer. Breast Cancer Research and Treatment, 2009, 118, 207-211.	1.1	42
201	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
202	MDM2 SNP309 T>G alone or in combination with theTP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. International Journal of Cancer, 2007, 120, 563-565.	2.3	41
203	Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk. BMC Cancer, 2008, 8, 112.	1.1	41
204	Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis, 2008, 29, 762-765.	1.3	41
205	Iron levels, genes involved in iron metabolism and antioxidative processes and lung cancer incidence. PLoS ONE, 2019, 14, e0208610.	1.1	41
206	Analysis of Germline Variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in Familial and Sporadic Renal Cell Carcinoma. PLoS ONE, 2009, 4, e6037.	1.1	40
207	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	3.0	40
208	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	1.4	40
209	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	1.4	40
210	Pathology of breast cancer in women with constitutional CHEK2 mutations. Breast Cancer Research and Treatment, 2005, 90, 187-189.	1.1	39
211	Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age. International Journal of Cancer, 2009, 125, 78-83.	2.3	39
212	Familial adenomatous polyposis of the colon. Hereditary Cancer in Clinical Practice, 2013, 11, 15.	0.6	39
213	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	1.5	39
214	Patient survival and tumor characteristics associated with CHEK2:p.I157T â€“ findings from the Breast Cancer Association Consortium. Breast Cancer Research, 2016, 18, 98.	2.2	39
215	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. European Urology, 2017, 72, 747-754.	0.9	39
216	The spectrum of mutations predisposing to familial breast cancer in Poland. International Journal of Cancer, 2019, 145, 3311-3320.	2.3	39

#	Article	IF	Citations
217	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39
218	MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk. International Journal of Cancer, 2006, 119, 2597-2602.	2.3	38
219	The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. International Journal of Cancer, 2012, 131, 229-234.	2.3	38
220	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	1.4	38
221	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility, 2016, 105, 781-785.	0.5	38
222	First Trimester Serum Copper or Zinc Levels, and Risk of Pregnancy-Induced Hypertension. Nutrients, 2019, 11, 2479.	1.7	38
223	Smoking Related Cancers and Loci at Chromosomes 15q25, 5p15, 6p22.1 and 6p21.33 in the Polish Population. PLoS ONE, 2011, 6, e25057.	1.1	37
224	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	2.6	37
225	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	0.5	37
226	Role of germline aberrations affecting CTNNA1, MAP3K6 and MYD88 in gastric cancer susceptibility. Journal of Medical Genetics, 2018, 55, 669-674.	1.5	37
227	11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 2012, 33, 1123-1132.	1.1	35
228	Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2014, 146, 421-427.	1.1	35
229	A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. European Journal of Human Genetics, 2003, 11, 955-958.	1.4	34
230	Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism inTP53. International Journal of Cancer, 2006, 118, 2479-2484.	2.3	34
231	Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?. European Journal of Cancer, 2009, 45, 837-842.	1.3	34
232	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
233	Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer. Breast Cancer Research and Treatment, 2014, 148, 615-622.	1.1	34
234	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34

#	Article	IF	Citations
235	Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. European Journal of Human Genetics, 2017, 25, 1246-1252.	1.4	34
236	Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. Breast Cancer Research and Treatment, 2008, 112, 581-584.	1.1	33
237	BRCA1 mutations and prostate cancer in Poland. European Journal of Cancer Prevention, 2008, 17, 62-66.	0.6	33
238	BRCA1 mutations and colorectal cancer in Poland. Familial Cancer, 2010, 9, 541-544.	0.9	33
239	Exploring the Link between Germline and Somatic Genetic Alterations in Breast Carcinogenesis. PLoS ONE, 2010, 5, e14078.	1.1	33
240	Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. Breast Cancer Research and Treatment, 2012, 132, 937-945.	1.1	33
241	Can selenium levels act as a marker of colorectal cancer risk?. BMC Cancer, 2013, 13, 214.	1.1	33
242	Combined analysis of three lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers. International Journal of Cancer, 2013, 132, 1556-1564.	2.3	33
243	A Rare Truncating BRCA2 Variant and Genetic Susceptibility to Upper Aerodigestive Tract Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	33
244	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
245	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 2016, 25, 3863-3876.	1.4	33
246	Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?. Gynecologic Oncology, 2017, 145, 346-351.	0.6	33
247	Serum Selenium Level in Early Healthy Pregnancy as a Risk Marker of Pregnancy Induced Hypertension. Nutrients, 2019, 11, 1028.	1.7	33
248	BRCA1 promoter methylation in peripheral blood is associated with the risk of tripleâ€negative breast cancer. International Journal of Cancer, 2020, 146, 1293-1298.	2.3	33
249	First Trimester Microelements and Their Relationships with Pregnancy Outcomes and Complications. Nutrients, 2020, 12, 1108.	1.7	33
250	CHEK2-Positive Breast Cancers in Young Polish Women. Clinical Cancer Research, 2006, 12, 4832-4835.	3.2	32
251	Elevated level of 8â€oxoâ€7,8â€dihydroâ€2â€²â€deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls. International Journal of Cancer, 2009, 125, 2209-2213.	2.3	32
252	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	1.4	32

#	Article	IF	Citations
253	Polymorphisms in nucleotide excision repair genes and susceptibility to colorectal cancer in the Polish population. Molecular Biology Reports, 2015, 42, 755-764.	1.0	32
254	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
255	A Genome-Wide Analysis of Populations from European Russia Reveals a New Pole of Genetic Diversity in Northern Europe. PLoS ONE, 2013, 8, e58552.	1.1	32
256	The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. Prostate, 2013, 73, 542-548.	1.2	31
257	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. Breast Cancer Research and Treatment, 2013, 138, 273-279.	1.1	31
258	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 2016, 7, 80140-80163.	0.8	31
259	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
260	Serum folate concentration and the incidence of lung cancer. PLoS ONE, 2017, 12, e0177441.	1.1	31
261	AURKAF31I Polymorphism and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1416-1421.	1.1	30
262	Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. International Journal of Cancer, 2015, 136, 1351-1360.	2.3	30
263	Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population. PLoS ONE, 2018, 13, e0201065.	1.1	30
264	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
265	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	5.8	30
266	Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer. International Journal of Cancer, 2008, 122, 583-586.	2.3	29
267	Nonalcoholic fatty liver disease andHFEgene mutations: A Polish study. World Journal of Gastroenterology, 2010, 16, 2531.	1.4	29
268	Auroraâ€A and Cyclin D1 polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer. International Journal of Cancer, 2008, 122, 1273-1277.	2.3	28
269	Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility. BMC Cancer, 2010, 10, 420.	1.1	28
270	CHEK2 mutations and HNPCCâ€related colorectal cancer. International Journal of Cancer, 2010, 126, 3005-3009.	2.3	28

#	Article	IF	Citations
271	Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 55-64.	1.4	28
272	International Rates of Breast Reconstruction After Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers. Annals of Surgical Oncology, 2013, 20, 3817-3822.	0.7	28
273	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	1.1	28
274	Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Familial Cancer, 2015, 14, 383-391.	0.9	28
275	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
276	Blood cadmium levels as a marker for early lung cancer detection. Journal of Trace Elements in Medicine and Biology, 2021, 64, 126682.	1.5	28
277	Vitamin D receptor variants and breast cancer risk in the Polish population. Breast Cancer Research and Treatment, 2009, 115, 629-633.	1.1	27
278	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. Breast Cancer Research and Treatment, 2009, 114, 127-135.	1.1	27
279	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptorâ€“Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	1.1	27
280	Genome-Wide Association Study of Prostate Cancerâ€“Specific Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1796-1800.	1.1	27
281	Sex specific associations in genome wide association analysis of renal cell carcinoma. European Journal of Human Genetics, 2019, 27, 1589-1598.	1.4	27
282	Mutations in ATM , NBN and BRCA2 predispose to aggressive prostate cancer in Poland. International Journal of Cancer, 2020, 147, 2793-2800.	2.3	27
283	The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs. Hereditary Cancer in Clinical Practice, 2005, 3, 59.	0.6	26
284	CDKN2A common variant and multi-organ cancer riskâ€”a population-based study. International Journal of Cancer, 2006, 118, 3180-3182.	2.3	26
285	BARD1 and breast cancer in Poland. Breast Cancer Research and Treatment, 2007, 107, 119-122.	1.1	26
286	Mitochondrial genotype and breast cancer predisposition. Oncology Reports, 2010, 24, 1521-34.	1.2	26
287	Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study. Cancer Causes and Control, 2012, 23, 1065-1074.	0.8	26
288	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26

#	Article	IF	Citations
289	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	2.2	26
290	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1495-1503.	1.9	26
291	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2016, 157, 319-327.	1.1	26
292	Population-based targeted sequencing of 54 candidate genes identifiesPALB2as a susceptibility gene for high-grade serous ovarian cancer. Journal of Medical Genetics, 2021, 58, 305-313.	1.5	26
293	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	1.1	26
294	The 30 kb deletion in the APOBEC3 cluster decreases APOBEC3A and APOBEC3B expression and creates a transcriptionally active hybrid gene but does not associate with breast cancer in the European population. Oncotarget, 2017, 8, 76357-76374.	0.8	26
295	IGF1 is a modifier of disease risk in hereditary nonâ€polyposis colorectal cancer. International Journal of Cancer, 2008, 123, 1339-1343.	2.3	25
296	DNA repair gene polymorphisms and risk of early onset colorectal cancer in Lynch syndrome. Cancer Epidemiology, 2012, 36, 183-189.	0.8	25
297	Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 169, 561-571.	1.1	25
298	Serum selenium levels and the risk of progression of laryngeal cancer. PLoS ONE, 2018, 13, e0184873.	1.1	25
299	Influence of the selenium level on overall survival in lung cancer. Journal of Trace Elements in Medicine and Biology, 2019, 56, 46-51.	1.5	25
300	BARD1 is a Low/Moderate Breast Cancer Risk Gene: Evidence Based on an Association Study of the Central European p.Q564X Recurrent Mutation. Cancers, 2019, 11, 740.	1.7	25
301	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
302	Germline mutation and large deletion analysis of theCDKN2A andARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer. International Journal of Cancer, 2004, 110, 558-562.	2.3	24
303	Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers. Breast, 2010, 19, 479-483.	0.9	24
304	A common nonsense mutation of the BLM gene and prostate cancer risk and survival. Gene, 2013, 532, 173-176.	1.0	24
305	Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. Breast Cancer Research and Treatment, 2014, 147, 113-118.	1.1	24
306	Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	1.3	24

#	Article	IF	Citations
307	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	1.1	24
308	The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. British Journal of Cancer, 2016, 114, 1160-1164.	2.9	24
309	The Role of Early Pregnancy Maternal Selenium Levels on the Risk for Small-for-Gestational Age Newborns. Nutrients, 2019, 11, 2298.	1.7	24
310	Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Research, 2019, 21, 144.	2.2	24
311	Genetic Polymorphisms in Xenobiotic Clearance Genes and Their Influence on Disease Expression in Hereditary Nonpolyposis Colorectal Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2307-2310.	1.1	23
312	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	1.1	23
313	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	1.8	23
314	Prevalence of the E318K and V320I MITF germline mutations in Polish cancer patients and multiorgan cancer risk-a population-based study. Cancer Genetics, 2014, 207, 128-132.	0.2	23
315	Common variants of xeroderma pigmentosum genes and prostate cancer risk. Gene, 2014, 546, 156-161.	1.0	23
316	Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study. American Journal of Clinical Nutrition, 2016, 104, 671-677.	2.2	23
317	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	2.9	23
318	Influence of the Levels of Arsenic, Cadmium, Mercury and Lead on Overall Survival in Lung Cancer. Biomolecules, 2021, 11, 1160.	1.8	23
319	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
320	Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. American Journal of Human Genetics, 2022, 109, 953-960.	2.6	23
321	CDKN2A-positive breast cancers in young women from Poland. Breast Cancer Research and Treatment, 2007, 103, 355-359.	1.1	22
322	Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk. Breast Cancer Research and Treatment, 2009, 117, 161-165.	1.1	22
323	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Human Molecular Genetics, 2011, 20, 2263-2272.	1.4	22
324	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	0.6	22

#	Article	IF	Citations
325	Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers. PLoS ONE, 2015, 10, e0130393.	1.1	22
326	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
327	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	1.4	22
328	Can Serum Iron Concentrations in Early Healthy Pregnancy Be Risk Marker of Pregnancy-Induced Hypertension?. Nutrients, 2019, 11, 1086.	1.7	22
329	Detection of germline mutations in the BRCA1 gene by RNA-based sequencing. Human Mutation, 2001, 18, 149-156.	1.1	21
330	High Incidence of 4153delA BRCA1 Gene Mutations in Lithuanian Breast- and Breast-ovarian Cancer Families. Breast Cancer Research and Treatment, 2005, 94, 111-113.	1.1	21
331	Epistatic Relationship between the Cancer Susceptibility Genes CHEK2 and p27. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 572-576.	1.1	21
332	Identification of Patients at High Risk of Psychological Distress After BRCA1 Genetic Testing. Genetic Testing and Molecular Biomarkers, 2009, 13, 325-330.	0.3	21
333	Large-Scale Evaluation of Common Variation in Regulatory T Cellâ€“Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	1.6	21
334	PARS PLANA VITRECTOMY IN ADVANCED CASES OF VON HIPPELâ€“LINDAU EYE DISEASE. Retina, 2016, 36, 325-334.	1.0	21
335	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	0.8	21
336	Pre-Pregnancy Obesity vs. Other Risk Factors in Probability Models of Preeclampsia and Gestational Hypertension. Nutrients, 2020, 12, 2681.	1.7	21
337	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e20703.	1.1	21
338	Inherited NBN Mutations and Prostate Cancer Risk and Survival. Cancer Research and Treatment, 2019, 51, 1180-1187.	1.3	21
339	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 987-992.	1.1	20
340	Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial. Breast, 2017, 34, 18-23.	0.9	20
341	The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation. Hereditary Cancer in Clinical Practice, 2017, 15, 15.	0.6	20
342	Predictors of survival for breast cancer patients with a BRCA1 mutation. Breast Cancer Research and Treatment, 2018, 168, 513-521.	1.1	20

#	Article	IF	Citations
343	The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 2018, 142, 2263-2272.	2.3	20
344	Monoallelic NTHL1 Loss-of-Function Variants and Risk of Polyposis and Colorectal Cancer. Gastroenterology, 2020, 159, 2241-2243.e6.	0.6	20
345	Lack of association between genetic polymorphisms in cytokine genes and disease expression in patients with hereditary non-polyposis colorectal cancer. Scandinavian Journal of Gastroenterology, 2007, 42, 628-632.	0.6	19
346	Association of MMP8 gene variation with an increased risk of malignant melanoma. Melanoma Research, 2011, 21, 464-468.	0.6	19
347	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	1.8	19
348	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Scientific Reports, 2016, 6, 32512.	1.6	19
349	The BRCA2 c.68-7TÂ>ÂA variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human Mutation, 2018, 39, 729-741.	1.1	19
350	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
351	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	1.1	19
352	The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome. Cancer Research and Treatment, 2017, 49, 430-436.	1.3	19
353	Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland. Biomedicines, 2021, 9, 1628.	1.4	19
354	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	3.6	19
355	CYP1B1 and predisposition to breast cancer in Poland. Breast Cancer Research and Treatment, 2007, 106, 383-388.	1.1	18
356	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	1.8	18
357	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
358	Blood arsenic levels and the risk of familial breast cancer in Poland. International Journal of Cancer, 2020, 146, 2721-2727.	2.3	18
359	PALB2 mutations and prostate cancer risk and survival. British Journal of Cancer, 2021, 125, 569-575.	2.9	18
360	MTHFR 677 C>T and 1298 A>C polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer. European Journal of Human Genetics, 2009, 17, 629-635.	1.4	17

#	Article	IF	Citations
361	Iniparib in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2011, 364, 1780-1781.	13.9	17
362	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Human Molecular Genetics, 2016, 25, 3600-3612.	1.4	17
363	Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. Hereditary Cancer in Clinical Practice, 2017, 15, 4.	0.6	17
364	A common missense variant in BRCA2 predisposes to early onset breast cancer. Breast Cancer Research, 2005, 7, R1023-7.	2.2	16
365	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038.	1.1	16
366	Association of common WRAP 53 variant with ovarian cancer risk in the Polish population. Molecular Biology Reports, 2013, 40, 2145-2147.	1.0	16
367	Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?. Mutagenesis, 2013, 28, 625-629.	1.0	16
368	Consortium analysis of gene and geneâ€“folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	1.5	16
369	Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?. International Journal of Cancer, 2016, 139, 601-606.	2.3	16
370	Serum 25(OH)D concentration, common variants of the VDR gene and lung cancer occurrence. International Journal of Cancer, 2017, 141, 336-341.	2.3	16
371	The Influence of Maternal BMI on Adverse Pregnancy Outcomes in Older Women. Nutrients, 2020, 12, 2838.	1.7	16
372	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
373	The 3â€² untranslated region CÂ>ÂT polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation. Breast Cancer Research and Treatment, 2007, 104, 67-74.	1.1	15
374	The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2010, 121, 639-649.	1.1	15
375	Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families. Molecular Biology Reports, 2013, 40, 6619-6623.	1.0	15
376	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	0.6	15
377	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	2.9	15
378	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	0.9	15

#	Article	IF	Citations
379	A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy. Gynecologic Oncology, 2019, 155, 270-274.	0.6	15
380	Serum selenium level and cancer risk: a nested case-control study. Hereditary Cancer in Clinical Practice, 2019, 17, 33.	0.6	15
381	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8⁺ TIL</scp> infiltration, and provides no independent prognostic value in endometriosisâ€associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	2.1	15
382	A Sex-Specific Association between a 15q25 Variant and Upper Aerodigestive Tract Cancers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 658-664.	1.1	14
383	High Resolution Melting analysis as a rapid and efficient method of screening for small mutations in the STK11gene in patients with Peutz-Jeghers syndrome. BMC Medical Genetics, 2013, 14, 58.	2.1	14
384	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	2.2	14
385	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	1.3	14
386	Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast, lung and colon cancer risk in polish population. Hereditary Cancer in Clinical Practice, 2020, 18, 16.	0.6	14
387	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. Breast Cancer Research and Treatment, 2020, 181, 423-434.	1.1	14
388	Serum Selenium Level Predicts 10-Year Survival after Breast Cancer. Nutrients, 2021, 13, 953.	1.7	14
389	Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland. European Journal of Cancer Prevention, 2008, 17, 389-391.	0.6	13
390	Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. Gynecologic Oncology, 2009, 115, 135-137.	0.6	13
391	Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology. Breast Cancer Research and Treatment, 2009, 114, 121-126.	1.1	13
392	Haplotype of the C61GBRCA1Mutation in Polish and Jewish Individuals. Genetic Testing and Molecular Biomarkers, 2009, 13, 465-469.	0.3	13
393	The rs1447295 and DG8S737 markers on chromosome 8q24 and cancer risk in the Polish population. European Journal of Cancer Prevention, 2010, 19, 167-171.	0.6	13
394	Variation in NF-ÎºB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	1.1	13
395	Inherited variants in XRCC2 and the risk of breast cancer. Breast Cancer Research and Treatment, 2019, 178, 657-663.	1.1	13
396	Lung Cancer Occurrenceâ€"Correlation with Serum Chromium Levels and Genotypes. Biological Trace Element Research, 2021, 199, 1228-1236.	1.9	13

#	Article	IF	Citations
397	Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer. Cancers, 2021, 13, 849.	1.7	13
398	Survival of Laryngeal Cancer Patients Depending on Zinc Serum Level and Oxidative Stress Genotypes. Biomolecules, 2021, 11, 865.	1.8	13
399	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	0.8	13
400	Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers. Oncotarget, 2016, 7, 68662-68673.	0.8	13
401	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	1.4	12
402	Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2015, 151, 435-441.	1.1	12
403	Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe. Familial Cancer, 2015, 14, 145-149.	0.9	12
404	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	1.1	12
405	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276.	2.9	12
406	Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland. Hereditary Cancer in Clinical Practice, 2018, 16, 6.	0.6	12
407	Serum selenium levels are associated with age-related cataract. Annals of Agricultural and Environmental Medicine, 2018, 25, 443-448.	0.5	12
408	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2019, 175, 443-449.	1.1	12
409	Identification of Familial Hodgkin Lymphoma Predisposing Genes Using Whole Genome Sequencing. Frontiers in Bioengineering and Biotechnology, 2020, 8, 179.	2.0	12
410	Survival from breast cancer in women with a BRCA2 mutation by treatment. British Journal of Cancer, 2021, 124, 1524-1532.	2.9	12
411	Integrin Â3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk. Journal of Medical Genetics, 2007, 44, 408-411.	1.5	11
412	Genetic Heterogeneity of 8q24 Region in Susceptibility to Cancer. Journal of the National Cancer Institute, 2009, 101, 278-279.	3.0	11
413	Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families. Hereditary Cancer in Clinical Practice, 2015, 13, 3.	0.6	11
414	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. International Journal of Epidemiology, 2018, 47, 987-997.	0.9	11

#	Article	IF	Citations
415	Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer. Cancers, 2019, 11, 1548.	1.7	11
416	Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland. Cancers, 2020, 12, 2321.	1.7	11
417	Germline Variants of CYBA and TRPM4 Predispose to Familial Colorectal Cancer. Cancers, 2022, 14, 670.	1.7	11
418	Association between early-onset breast and laryngeal cancers. Breast Cancer Research and Treatment, 2006, 97, 215-219.	1.1	10
419	Frequency of mutations related to hereditary haemochromatosis in northwestern Poland. Journal of Applied Genetics, 2008, 49, 105-107.	1.0	10
420	CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland. Familial Cancer, 2010, 9, 605-608.	0.9	10
421	Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers. Obesity, 2012, 20, 1288-1292.	1.5	10
422	The 12p13.33/RAD52 Locus and Genetic Susceptibility to Squamous Cell Cancers of Upper Aerodigestive Tract. PLoS ONE, 2015, 10, e0117639.	1.1	10
423	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
424	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 171, 421-426.	1.1	10
425	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2020, 159, 820-826.	0.6	10
426	Prevalence of germline TP53 variants among early-onset breast cancer patients from Polish population. Breast Cancer, 2021, 28, 226-235.	1.3	10
427	Dupuytrenâ€™s disease and the risk of malignant neoplasms. Hereditary Cancer in Clinical Practice, 2014, 12, 6.	0.6	9
428	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 446-454.	1.1	9
429	BRCA1/2â€negative hereditary tripleâ€negative breast cancers exhibit BRCAness. International Journal of Cancer, 2017, 140, 1545-1550.	2.3	9
430	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	1.1	9
431	Prevalence and spectrum of MLH1, MSH2, and MSH6 pathogenic germline variants in Pakistani colorectal cancer patients. Hereditary Cancer in Clinical Practice, 2019, 17, 29.	0.6	9
432	A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report. European Journal of Human Genetics, 2021, 29, 1354-1358.	1.4	9

#	Article	IF	Citations
433	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	2.9	9
434	PHIP- a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 2017, 8, 102769-102782.	0.8	9
435	Comparison of Alu-PCR, microsatellite instability, and immunohistochemical analyses in finding features characteristic for hereditary nonpolyposis colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2001, 127, 565-569.	1.2	8
436	Nuclear Pedigree Criteria of Suspected HNPCC. Hereditary Cancer in Clinical Practice, 2003, 1, 1.	0.6	8
437	Combined iPLEX and TaqMan Assays to Screen for 45 Common Mutations in Lynch Syndrome and FAP Patients. Journal of Molecular Diagnostics, 2010, 12, 82-90.	1.2	8
438	The HOXB13 p.Gly84Glu mutation is not associated with the risk of breast cancer. Breast Cancer Research and Treatment, 2012, 136, 907-909.	1.1	8
439	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Human Genetics, 2016, 135, 137-154.	1.8	8
440	Serum Selenium Level and 10-Year Survival after Melanoma. Biomedicines, 2021, 9, 991.	1.4	8
441	BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update. Hereditary Cancer in Clinical Practice, 2021, 19, 13.	0.6	8
442	Founder Mutations for Early Onset Melanoma as Revealed by Whole Exome Sequencing Suggests That This is Not Associated with the Increasing Incidence of Melanoma in Poland. Cancer Research and Treatment, 2019, 51, 337-344.	1.3	8
443	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2022, 164, 514-521.	0.6	8
444	Population Screening for Cancer Family Syndromes in the West Pomeranian Region of Poland. Hereditary Cancer in Clinical Practice, 2006, 4, 56.	0.6	7
445	Hereditary breast and ovarian cancer. Hereditary Cancer in Clinical Practice, 2008, 6, 88.	0.6	7
446	The 4154delA mutation carriers in the BRCA1 gene share a common ancestry. Familial Cancer, 2009, 8, 1-4.	0.9	7
447	Pedigree based DNA sequencing pipeline for germline genomes of cancer families. Hereditary Cancer in Clinical Practice, 2016, 14, 16.	0.6	7
448	BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population. Hereditary Cancer in Clinical Practice, 2016, 14, 3.	0.6	7
449	Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers. Breast Cancer Research and Treatment, 2019, 174, 769-774.	1.1	7
450	Serum Microelements in Early Pregnancy and their Risk of Large-for-Gestational Age Birth Weight. Nutrients, 2020, 12, 866.	1.7	7

#	Article	IF	Citations
451	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	2.2	7
452	Genetic predisposition to male breast cancer in Poland. BMC Cancer, 2021, 21, 975.	1.1	7
453	Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations. Familial Cancer, 2009, 8, 473-478.	0.9	6
454	Zinc and breast cancer risk. Hereditary Cancer in Clinical Practice, 2012, 10, A6.	0.6	6
455	The presence of prostate cancer at biopsy is predicted by a number of genetic variants. International Journal of Cancer, 2014, 134, 1139-1146.	2.3	6
456	BRCA1 founder mutations compared to ovarian cancer in Belarus. Familial Cancer, 2014, 13, 445-447.	0.9	6
457	Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?. Breast Cancer Research and Treatment, 2015, 154, 163-169.	1.1	6
458	A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome. Hereditary Cancer in Clinical Practice, 2016, 14, 14.	0.6	6
459	BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population. PLoS ONE, 2018, 13, e0204768.	1.1	6
460	Allelic modification of breast cancer risk in women with an NBN mutation. Breast Cancer Research and Treatment, 2019, 178, 427-431.	1.1	6
461	Whole Exome Sequencing Identifies APCDD1 and HDAC5 Genes as Potentially Cancer Predisposing in Familial Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 1837.	1.8	6
462	A genetic variant in telomerase reverse transcriptase (TERT) modifies cancer risk in Lynch syndrome patients harbouring pathogenic MSH2 variants. Scientific Reports, 2021, 11, 11401.	1.6	6
463	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	2.6	6
464	Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers. Cancers, 2021, 13, 3345.	1.7	6
465	Weight Gain and the Risk of Ovarian Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2038-2043.	1.1	6
466	Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism. BMC Cancer, 2008, 8, 90.	1.1	5
467	Lynch syndrome (HNPCC). Hereditary Cancer in Clinical Practice, 2008, 6, 99.	0.6	5
468	Acute myeloid leukemia in a 38-year-old hemodialyzed patient with von Hippel-Lindau disease. Hereditary Cancer in Clinical Practice, 2013, 11, 11.	0.6	5

#	Article	IF	Citations
469	Large deletion causing von Hippel-Lindau disease and hereditary breast cancer syndrome. Hereditary Cancer in Clinical Practice, 2014, 12, 16.	0.6	5
470	Cumulative Small Effect Genetic Markers and the Risk of Colorectal Cancer in Poland, Estonia, Lithuania, and Latvia. Gastroenterology Research and Practice, 2015, 2015, 1-10.	0.7	5
471	The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men. European Journal of Cancer Prevention, 2015, 24, 122-127.	0.6	5
472	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	1.6	5
473	The intron 3 16Âbp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer. Breast Cancer Research and Treatment, 2019, 173, 727-733.	1.1	5
474	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. Menopause, 2020, 27, 156-161.	0.8	5
475	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	2.9	5
476	Breast cancer risk after age 60 amongÂBRCA1 andÂBRCA2 mutation carriers. Breast Cancer Research and Treatment, 2021, 187, 515-523.	1.1	5
477	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	0.8	5
478	An Assessment of GPX1 (rs1050450), DIO2 (rs225014) and SEPP1 (rs7579) Gene Polymorphisms in Women with Endometrial Cancer. Genes, 2022, 13, 188.	1.0	5
479	Breast cancer susceptibility genes. Journal of B U on, 2007, 12 Suppl 1, S23-9.	0.4	5
480	Risk of Second Primary Thyroid Cancer in Women with Breast Cancer. Cancers, 2022, 14, 957.	1.7	5
481	Spectrum and frequency of CHEK2 variants in breast cancer affected and general population in the Baltic states region, initial results and literature review. European Journal of Medical Genetics, 2022, 65, 104477.	0.7	5
482	A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet. Hereditary Cancer in Clinical Practice, 2006, 4, 58.	0.6	4
483	Review Selenium as aÂmarker of cancer risk and of selection for control examinations in surveillance. Wspolczesna Onkologia, 2015, 1A, 60-61.	0.7	4
484	Association of ABCA4 Gene Polymorphisms with Cleft Lip with or without Cleft Palate in the Polish Population. International Journal of Environmental Research and Public Health, 2021, 18, 11483.	1.2	4
485	Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor. Hereditary Cancer in Clinical Practice, 2022, 20, 11.	0.6	4
486	The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations. British Journal of Cancer, 2022, 127, 84-91.	2.9	4

#	Article	IF	Citations
487	Modest association of malignant melanoma with the rs910873 and rs1885120 markers on chromosome 20: a population-based study. Melanoma Research, 2010, 20, 159-160.	0.6	3
488	The CYP17A1 â^'34TÂ>ÂC polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2011, 126, 521-527.	1.1	3
489	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	1.1	3
490	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
491	Constitutional variants in POT1, TERF2IP, and ACD genes in patients with melanoma in the Polish population. European Journal of Cancer Prevention, 2020, 29, 511-519.	0.6	3
492	Genetic Epidemiology Studies in Hereditary Non-Polyposis Colorectal Cancer. Methods in Molecular Biology, 2009, 472, 89-102.	0.4	3
493	Selenium as marker for cancer risk and prevention. Polski Przeglad Chirurgiczny, 2012, 84, 470-5.	0.2	3
494	Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1351-1358.	1.1	3
495	Clinical characteristics of tumors derived from colorectal cancer patients who harbor the Tumor Necrosis Factor Î±-1031T/T and NOD2 3020insC polymorphism. Cancer Epidemiology, 2009, 33, 161-163.	0.8	2
496	A case of carotid body paraganglioma and haemangioblastoma of the spinal cord in a patient with the N131K missense mutation in the VHL gene. Neurological Sciences, 2011, 32, 491-496.	0.9	2
497	From Phenotype to Genotype: A New Twist on Identifying Genes Responsible for Inherited Hearing Loss. Human Mutation, 2013, 34, v-v.	1.1	2
498	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Human Molecular Genetics, 2013, 22, 4239-4239.	1.4	2
499	Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone. Hereditary Cancer in Clinical Practice, 2013, 11, 17.	0.6	2
500	Genotyping by Induced FÃ¶rster Resonance Energy Transfer (iFRET) Mechanism and Simultaneous Mutation Scanning. Human Mutation, 2013, 34, n/a-n/a.	1.1	2
501	Breast cancer genetics: 20â€‰years later. Clinical Genetics, 2014, 85, 5-6.	1.0	2
502	Weight Gain After Oophorectomy Among Women with a BRCA1 or BRCA2 Mutation. Women's Health, 2015, 11, 453-459.	0.7	2
503	rs2735383, located at a microRNA binding site in the 3â€™UTR of NBS1, is not associated with breast cancer risk. Scientific Reports, 2016, 6, 36874.	1.6	2
504	Reply to â€˜Mutations in RECQL are not associated with breast cancer risk in an Australian populationâ€™. Nature Genetics, 2018, 50, 1348-1349.	9.4	2

#	Article	IF	Citations
505	Genetic polymorphisms may influence the vertical growth rate of melanoma. Journal of Cancer, 2018, 9, 3078-3083.	1.2	2
506	Populationâ€based identityâ€byâ€descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 223-231.	1.1	2
507	Cancer Predisposition Genes in Cancer-Free Families. Cancers, 2020, 12, 2770.	1.7	2
508	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	1.6	2
509	A rare large duplication of MLH1 identified in Lynch syndrome. Hereditary Cancer in Clinical Practice, 2021, 19, 10.	0.6	2
510	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	1.6	2
511	Whole-Exome Sequencing Identifies a Novel Germline Variant in PTK7 Gene in Familial Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 1295.	1.8	2
512	HFE gene mutations in patients with alcoholic liver disease. A prospective study from northwestern Poland. , 2010, 120, 127-31.		2
513	An Assessment of Serum Selenium Concentration in Women with Endometrial Cancer. Nutrients, 2022, 14, 958.	1.7	2
514	Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland. Hereditary Cancer in Clinical Practice, 2022, 20, 13.	0.6	2
515	Psoriasis vulgaris and familial cancer risk- a population-based study. Hereditary Cancer in Clinical Practice, 2013, 11, 6.	0.6	1
516	First recurrent large genomic rearrangement in the BRCA1 gene found in Poland. Cancer Epidemiology, 2014, 38, 382-385.	0.8	1
517	Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy. Hereditary Cancer in Clinical Practice, 2019, 17, 10.	0.6	1
518	Recurrent PALB2 mutations and the risk of cancers of bladder or kidney in Polish population. Hereditary Cancer in Clinical Practice, 2021, 19, 6.	0.6	1
519	Abstract 878: Contraceptive use and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Cancer Research, 2021, 81, 878-878.	0.4	1
520	Survival of bladder or renal cancer in patients with CHEK2 mutations. PLoS ONE, 2021, 16, e0257132.	1.1	1
521	CHAPTER 22. Selenium and Cancer. Food and Nutritional Components in Focus, 2015, , 377-390.	0.1	1
522	Possible association of the BRCA2 gene C5972T variant with gastric cancer: a study on Polish population. Polish Archives of Internal Medicine, 2015, 125, 39-45.	0.3	1

#	Article	IF	Citations
523	Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?. Cancers, 2021, 13, 5464.	1.7	1
524	Common Variant in ALDH2 Modifies the Risk of Breast Cancer Among Carriers of the p.K3326* Variant in BRCA2. JCO Precision Oncology, 2022, 6, e2100450.	1.5	1
525	Whole exome sequencing identifies novel germline variants of SLC15A4 gene as potentially cancer predisposing in familial colorectal cancer. Molecular Genetics and Genomics, 2022, , 1.	1.0	1
526	Familial association of laryngeal, lung, stomach and early-onset breast cancer. Breast Cancer Research and Treatment, 2008, 112, 359-361.	1.1	0
527	Principles of genetic predisposition to malignancies. Hereditary Cancer in Clinical Practice, 2008, 6, 69.	0.6	0
528	Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair. Obstetrical and Gynecological Survey, 2015, 70, 758-762.	0.2	0
529	A Novel Low-Risk Germline Variant in the SH2 Domain of the SRC Gene Affects Multiple Pathways in Familial Colorectal Cancer. Journal of Personalized Medicine, 2021, 11, 262.	1.1	0
530	Abstract 857: Evaluating the relationship between arsenic exposure and cancer risk in Canada. , 2021, , .		0
531	Low Blood-As Levels and Selected Genotypes Appears to Be Promising Biomarkers for Occurrence of Colorectal Cancer in Women. Biomedicines, 2021, 9, 1105.	1.4	0
532	Abstract 4172: Identification of familial Hodgkin lymphoma predisposing genes by whole genome sequencing. , 2019, , .		0
533	Germline HOXB13 mutation p.G84E do not confer an increased bladder or kidney cancer risk in polish population. Hereditary Cancer in Clinical Practice, 2022, 20, 1.	0.6	0
534	Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland. Hereditary Cancer in Clinical Practice, 2022, 20, 12.	0.6	0
535	Bladder cancer survival in patients with NOD2 or CDKN2A variants. Oncotarget, 2022, 13, 628-640.	0.8	0